Flu Vaccine Market is expected to Hit US$ 10.74 billion by 2033 | Major Companies - AstraZeneca, Sanofi, CSL, Viatris Inc., Sinovac Biotech Ltd.

DataM Intelligence has unveiled its latest report on the "Flu Vaccine Market Size 2026" delivering powerful insights into key trends, future growth opportunities, and evolving market challenges. Designed to empower smarter decision-making, the report equips businesses with the strategic intelligence needed to stay ahead in a competitive landscape. By blending robust qualitative analysis with data-driven quantitative research, DataM Intelligence offers a well-rounded perspective that helps organizations decode complex market dynamics, unlock new avenues for growth, and seize emerging opportunities in an ever-evolving global market.

Unlock Strategic Partnerships in the Growing Flu Vaccine Market-Connect with Key Industry Leaders Today: https://www.datamintelligence.com/partner-identification-enquiry/flu-vaccine-market?sz

The Global Flu Vaccine Market size reached US$ 6.12 billion in 2025 and is expected to reach US$ 10.74 billion by 2033, growing at a CAGR of 7.3% during the forecast period 2026-2033.

The Flu Vaccine Market refers to the global industry involved in the research, development, production, distribution, and commercialization of vaccines designed to protect against influenza viruses. It includes seasonal and pandemic influenza vaccines that help reduce infection rates, hospitalizations, and mortality. The market is driven by recurring annual demand due to virus mutation, public health immunization programs, and government initiatives. It spans pharmaceutical companies, biotech firms, and healthcare providers working to ensure widespread preventive immunization globally.

Download Free Sample Report (Get Higher Priority for Corporate Email ID): https://datamintelligence.com/download-sample/flu-vaccine-market?sz

Recent Industry Developments: United States

✅ March 2026: FDA advisory committee recommended updating flu vaccine strain composition for the 2026-2027 season, including a newly dominant H3N2 subclade variant.
This update triggered recalibration across U.S. vaccine manufacturers for seasonal production planning and supply chain adjustments.

✅ February 2026: The FDA initially rejected Moderna's mRNA-based flu vaccine application, citing concerns over clinical trial design and comparator standards.
Shortly after, the FDA reversed its decision and agreed to review an amended application, marking a major regulatory turnaround and renewed momentum for next-generation mRNA flu vaccines.

✅ January 2026: FDA initiated stricter regulatory scrutiny on influenza vaccines, including updated safety labeling requirements for pediatric flu shots, increasing compliance pressure on manufacturers.
Vaccine developers reported growing uncertainty in the U.S. market due to shifting federal guidance on immunization policies and approval pathways.

Recent Industry Developments: Japan

✅ April 2026: Japanese healthcare stakeholders began evaluating combined respiratory vaccine strategies, including flu-COVID combination vaccine concepts emerging from global approvals in other regions.
Distribution networks prepared for increased demand ahead of the 2026-2027 flu season, especially in urban aging populations.

✅ February 2026: Japan aligned with global influenza surveillance updates (WHO-linked strain forecasting), prompting early technical assessment of next-season flu vaccine strain matching.
Pharmaceutical companies in Japan accelerated formulation planning for quadrivalent influenza vaccines in response to expected strain shifts.

✅ January 2026: Japanese public health authorities expanded influenza vaccination planning for the 2026 season, focusing on higher-risk elderly populations amid rising post-pandemic flu variability.
Vaccine procurement discussions increased between domestic distributors and global manufacturers to secure early-season supply.

Speak to Our Analyst and Get Customization in the report as per your requirements: https://datamintelligence.com/customize/flu-vaccine-market?sz

List of the Key Players in the Flu Vaccine Market:

AstraZeneca
Sanofi
CSL
Serum Institute of India Pvt. Ltd
Viatris Inc.
Hualan Biological Engineering Inc
Sinovac Biotech Ltd.
GSK Plc
Pfizer Inc.
CureVac N.V.

How Does Market Research Work in the Flu Vaccine Market?

Market research for the Flu Vaccine Market involves systematic data collection and analysis to understand industry trends, customer behavior, and competitive dynamics. It includes primary research such as surveys and interviews, and secondary research from reports, databases, and publications. Analysts evaluate market size, growth drivers, challenges, and opportunities using qualitative and quantitative methods. Insights are validated through expert opinions and forecasting models, enabling businesses to make strategic decisions, identify target segments, and gain a competitive advantage in a rapidly evolving market.

Latest Mergers and Acquisitions of Flu Vaccine Market:

✅ April 2026: Chiesi Group to acquire KalVista Pharmaceuticals (rare disease + immunology expansion)
➠ Chiesi agreed to a $1.9 billion acquisition of KalVista Pharmaceuticals, adding advanced oral immunology therapies (including on-demand biologic treatments). While not a pure flu vaccine deal, it strengthens Chiesi's immunology and respiratory disease portfolio, which overlaps with infectious disease and vaccine-adjacent platforms.

✅ February 2026: Sanofi completes acquisition of Dynavax Technologies (Vaccine expansion)
➠ Sanofi finalized the acquisition of Dynavax, gaining its HEPLISAV-B vaccine platform and experimental vaccine pipeline, including assets tied to immunization technologies that support broader infectious disease and influenza-related vaccine development capabilities.

✅ January 2026: Merck acquires Cidara Therapeutics (Influenza prevention asset)
➠ Merck completed a $9.2 billion acquisition of Cidara Therapeutics, adding CD388, a long-acting antiviral designed for flu prevention across multiple strains. This strengthens Merck's respiratory and infectious disease pipeline and expands its influenza-prevention strategy beyond traditional vaccines.

Segments Covered in the Flu Vaccine Market 2026:

By Type: Inactivated Vaccines, Live Attenuated Vaccines, Recombinant Vaccines.

By Application: Children Less than 3 Years, Adults and Children Greater than 3 years.

Regional Analysis of the Flu Vaccine Market:

⇥ North America: Leads the market due to advanced infrastructure, strong R&D investments, and early adoption of new technologies.

⇥ Europe: Shows steady growth supported by strict regulations and increasing focus on sustainability initiatives.

⇥ Asia-Pacific: Fastest-growing region driven by rapid industrialization, urbanization, and rising consumer demand in emerging economies.

⇥ Latin America: Experiences moderate growth with expansion in industrial and commercial sectors.

⇥ Middle East & Africa: Gradual market growth supported by increasing investments and improving economic conditions.

Looking For Full Report? Get it Here: https://www.datamintelligence.com/buy-now-page?report=flu-vaccine-market

Key Benefits of the Report:

⏩ Comprehensive Market Insights: Gain a deep understanding of market size, trends, and structure.

⏩ Accurate Forecasting: Access reliable future projections to support long-term planning.

⏩ Competitive Analysis: Identify key players, strategies, and positioning in the market.

⏩ Data-Driven Decisions: Make informed business choices backed by verified data.

⏩ Opportunity Identification: Discover emerging trends and untapped growth areas.

⏩ Risk Mitigation: Reduce uncertainties with thorough market evaluation.

⏩ Customer Insights: Understand consumer behavior, preferences, and buying patterns.

⏩ Strategic Planning Support: Align business strategies with market realities.

⏩ Time & Cost Efficiency: Save resources by leveraging ready-to-use research.

⏩ Customization & Expert Validation: Benefit from tailored insights and industry expert analysis.

Unlock 360° Market Intelligence with DataM Subscription Services: https://www.datamintelligence.com/reports-subscription

People Also Ask:

◆ How big is the Flu Vaccine Market in 2025?
◆ What is the projected growth rate of the Flu Vaccine Market through 2033?
◆ Who are the key players in the Flu Vaccine Market?
◆ Which region is expected to dominate the industry during the forecast period?

Contact Us -
Company Name: DataM Intelligence
Contact Person: Fabian
Email: fabian@datamintelligence.com
Phone USA: +1 877-441-4866
Phone UK: +44 161-870-5507
Website:https://www.datamintelligence.com

About Us -
DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.
Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.